Garden Grove, CA8 Active Studies

Schizophrenia Clinical Trials in Garden Grove, CA

Find 8 actively recruiting schizophrenia clinical trials in Garden Grove, CA. Connect with local research sites and explore new treatment options.

8
Active Trials
8
Sponsors
2,916
Enrolling

Recruiting Schizophrenia Studies in Garden Grove

RecruitingGarden Grove, CANCT05184335

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg o...

690 participants
Reviva Pharmaceuticals
View Study Details
RecruitingGarden Grove, CANCT06894212

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia...

522 participants
Otsuka Pharmaceutical Development & Commercialization, Inc.
View Study Details
RecruitingGarden Grove, CANCT06229210

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder....

500 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingGarden Grove, CANCT07038876

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants age...

300 participants
MapLight Therapeutics
View Study Details
RecruitingGarden Grove, CANCT07105098

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults....

284 participants
Neurocrine Biosciences
View Study Details
RecruitingGarden Grove, CANCT05304767

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inade...

280 participants
Karuna Therapeutics
View Study Details
RecruitingGarden Grove, CANCT07145918

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess advers...

258 participants
AbbVie
View Study Details
RecruitingGarden Grove, CANCT06502964

Study of ALTO-101 in Patients With Schizophrenia

This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers an...

82 participants
Alto Neuroscience
View Study Details

About Schizophrenia Clinical Trials in Garden Grove

Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.

There are currently 8 schizophrenia clinical trials recruiting participants in Garden Grove, CA. These studies are seeking a combined 2,916 participants. Research is being sponsored by Reviva Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Inc., Intra-Cellular Therapies, Inc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Schizophrenia Clinical Trials in Garden Grove — FAQ

Are there schizophrenia clinical trials in Garden Grove?

Yes, there are 8 schizophrenia clinical trials currently recruiting in Garden Grove, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Garden Grove?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Garden Grove research site will contact you about next steps.

Are clinical trials in Garden Grove free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Garden Grove studies also compensate for your time and travel.

What schizophrenia treatments are being tested?

The 8 active trials in Garden Grove are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.

Data updated March 2, 2026 from ClinicalTrials.gov